Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
L Cai, Y Li, J Tan, L Xu, Y Li - Journal of hematology & oncology, 2023 - Springer
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
[HTML][HTML] TIGIT in cancer immunotherapy
JM Chauvin, HM Zarour - Journal for immunotherapy of cancer, 2020 - ncbi.nlm.nih.gov
Tumors evade immune-mediated recognition through multiple mechanisms of immune
escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and …
escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and …
[HTML][HTML] Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses
KL Banta, X Xu, AS Chitre, A Au-Yeung, C Takahashi… - Immunity, 2022 - cell.com
Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
S Qin, L Xu, M Yi, S Yu, K Wu, S Luo - Molecular cancer, 2019 - Springer
The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed
cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T …
cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T …
Impact of COVID‐19 pandemic on liver transplantation and alcohol‐associated liver disease in the USA
Involvement of TIGIT in Natural Killer Cell Exhaustion and I... : Hepatology Involvement of
TIGIT in Natural Killer Cell Exhaustion and Immune Escape in Patients and Mouse Model With …
TIGIT in Natural Killer Cell Exhaustion and Immune Escape in Patients and Mouse Model With …
[HTML][HTML] First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small …
Background In this first-in-human phase 1 study (NCT02964013; MK-7684-001), we
investigated the safety and efficacy of the anti-TIGIT (T cell immunoglobulin and ITIM …
investigated the safety and efficacy of the anti-TIGIT (T cell immunoglobulin and ITIM …
TIGIT as an emerging immune checkpoint
H Harjunpää, C Guillerey - Clinical & Experimental Immunology, 2020 - academic.oup.com
T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on
lymphocytes that was recently propelled under the spotlight as a major emerging target in …
lymphocytes that was recently propelled under the spotlight as a major emerging target in …
Fundamental mechanisms of immune checkpoint blockade therapy
SC Wei, CR Duffy, JP Allison - Cancer discovery, 2018 - AACR
Immune checkpoint blockade is able to induce durable responses across multiple types of
cancer, which has enabled the oncology community to begin to envision potentially curative …
cancer, which has enabled the oncology community to begin to envision potentially curative …
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Checkpoint blockade enhances effector T cell function and has elicited long-term remission
in a subset of patients with a broad spectrum of cancers. TIGIT is a checkpoint receptor …
in a subset of patients with a broad spectrum of cancers. TIGIT is a checkpoint receptor …